Bugge J F, Stokke E S, Vikse A, Kiil F
University of Oslo, Institute for Experimental Medical Research, Ullevaal Hospital, Norway.
Acta Physiol Scand. 1990 Feb;138(2):193-201. doi: 10.1111/j.1748-1716.1990.tb08833.x.
This study on 19 anaesthetized dogs had two objectives. The first was to compare the potencies of PGE2 and PGI2 as stimulators of renin release and demonstrate their dependency on activation of intrarenal mechanisms for renin release. The second objective was to demonstrate that ethacrynic acid (ECA) increases renin release not as a stimulator, but by activating intrarenal mechanisms. After inhibiting renal prostaglandin synthesis by indomethacin, PGE2 and PGI2 infused into the aorta proximal to the renal arteries exerted no significant effects on renin release, but increased renin release during ureteral occlusion. At equimolar infusion rates, PGI2 increased renin release twice as much as PGE2, but this difference in potency may reflect differences in degradation since 86% of PGE2 and 29% of PGI2 (measured as 6-keto-PGF1 alpha) were degraded during one passage through the kidney. By infusing PGF2 at 8 nmol min-1 and PGI2 at 2 nmol min-1 renin release increased equally and the prostaglandin outputs increased to the same levels as during ureteral occlusion before indomethacin administration. ECA did not increase renin release after indomethacin administration. However, infusion of PGE2 during continuous ECA administration increased renin release in a dose-dependent manner similar to the experiments performed during ureteral occlusion. We conclude that PGI2 and PGE2 in the amounts synthesized in the kidney seem to be equally important stimulators of renin release but their relative potencies cannot be determined because the site of degradation is uncertain. Renin release is enhanced by intrarenal mechanisms activated by ECA infusion or ureteral occlusion, which both cause autoregulatory vasodilation and reduce NaCl reabsorption at the macula densa.
这项针对19只麻醉犬的研究有两个目的。第一个目的是比较前列腺素E2(PGE2)和前列环素(PGI2)作为肾素释放刺激剂的效能,并证明它们对肾内肾素释放机制激活的依赖性。第二个目的是证明依他尼酸(ECA)增加肾素释放并非作为刺激剂,而是通过激活肾内机制。在用吲哚美辛抑制肾前列腺素合成后,注入肾动脉近端主动脉的PGE2和PGI2对肾素释放无显著影响,但在输尿管阻塞期间增加了肾素释放。在等摩尔输注速率下,PGI2增加肾素释放的量是PGE2的两倍,但这种效能差异可能反映了降解差异,因为在一次通过肾脏的过程中,86%的PGE₂和29%的PGI₂(以6-酮-前列腺素F1α测量)被降解。通过以8 nmol min⁻¹的速率输注前列腺素F2(PGF2)和以2 nmol min⁻¹的速率输注PGI2,肾素释放等量增加,且前列腺素输出增加到与吲哚美辛给药前输尿管阻塞期间相同的水平。吲哚美辛给药后,ECA未增加肾素释放。然而,在持续给予ECA期间输注PGE2以剂量依赖性方式增加肾素释放,类似于输尿管阻塞期间进行的实验。我们得出结论,肾脏合成量的PGI2和PGE2似乎是肾素释放同样重要的刺激剂,但由于降解部位不确定,它们的相对效能无法确定。ECA输注或输尿管阻塞激活的肾内机制增强了肾素释放,这两种情况都会导致自身调节性血管舒张并减少致密斑处的氯化钠重吸收。